• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Hospital-Acquired C difficile Increases Length of Stay


Hospital-acquired Clostridium difficile infections significantly prolong hospitalizations independent of patients' baseline risk for death, but the magnitude of the effect may not be as large as some researchers have estimated, according to the authors of a retrospective study from Canada.

Patients with hospital-acquired C difficile infections spent a median of 6 days longer in the hospital than patients without infections, according to an analysis of hospital admissions between July 1, 2002, and Mar. 31, 2009, which controlled for severity of illness. The study, by Alan J. Forster, MD, and colleagues from the Ottawa Hospital Research Institute and University of Ottawa, Ontario, Canada, was published online December 5 in the Canadian Medical Association Journal.

Previous studies estimated that C difficile infections extend hospital stays anywhere from 1 to 3 weeks, the investigators write. However, those studies did not take into account the fact that the longer patients stay in the hospital, the more likely they are to acquire C difficile.

"We found that the impact of hospital-acquired C. difficile on length of stay is more conservative than previous estimates have suggested. Nevertheless, the impact remains large, especially when one considers the aggregated impact. Future studies should incorporate a formal cost analysis and measure patient outcomes from a broader perspective," they conclude.

Read the full article at:http://www.medscape.com/viewarticle/754906?sssdmh=dm1.740456&src=nldne

Source: Medscape Medical News

Related Videos
Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health
Sarah Bajorek, PhD, BCACP, MBA.
Pat Van Burkleo
Video 11 - "Social Burden and Goals of Therapy for Patients with Bronchiectasis"
Video 7 - "Harnessing Continuous Glucose Monitors for Type 1 Diabetes Management + Closing Words"
dr monica li
dr lawrence eichenfield
Dr Kevin Mallow, PharmD, BCPS, BC-ADM, CDCES
Video 14 - "Achieving Equitable Representation in Clinical Studies"
Related Content
© 2024 MJH Life Sciences
All rights reserved.